• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
NBRV

NBRV

Nabriva Therapeutics plc

NASDAQHealthcareBiotechnologyIE

USD1.42

+0.01 (+0.71%)

Company Profile

CEO

Colin Broom

IPO Date

2017-06-23

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

IE

Market Metrics

Open

$1.45

Prev. Close

$1.41

Day Low

$1.35

Day High

$1.90

52W Low

$1.22

52W High

$8.45

Market Cap

$0.00B

Volume

0.71M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

30.2%

Avg Negative

17.0%

Avg Neutral

52.7%

News Feed

Nabriva Therapeutics to Report Second Quarter 2021 Financial Results and Recent Corporate Highlights on August 5, 2021

GlobeNewsWire·7/22/2021·↑ positive

Down 15.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Nabriva Therapeutics AG (NBRV)

Zacks Investment Research·7/14/2021·↓ negative

Nabriva Agrees to Extension of Principal Debt Repayments Under Existing Loan Agreement with Hercules Capital

GlobeNewsWire·6/3/2021·↓ negative

Nabriva Announces Changes to its Board of Directors

GlobeNewsWire·6/2/2021·↑ positive

Why Nabriva Therapeutics Stock Is Surging Today

Benzinga·5/26/2021·↑ positive

NBRV Stock Price: Over 60% Increase Pre-Market Explanation

Pulse2·5/26/2021·↑ positive

Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP)

GlobeNewsWire·5/25/2021·↑ positive

Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference

GlobeNewsWire·5/21/2021·↑ positive

Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/9/2021·↓ negative

Nabriva Therapeutics to Report First Quarter 2021 Financial Results and Recent Corporate Highlights on May 6, 2021

GlobeNewsWire·4/29/2021·↑ positive